Departamento académico
(FM) Oncología
Publications (40) Publications auxquelles un chercheur a participé
2024
-
A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial
Future oncology (London, England), Vol. 20, Núm. 13, pp. 799-809
-
Access to melanoma drugs in Spain: a cross-sectional survey
Clinical and Translational Oncology
-
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer
Molecular Cancer, Vol. 23, Núm. 1
-
An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum (SUROVA trial)
International Journal of Gynecological Cancer, Vol. 34, Núm. 6, pp. 942-945
-
Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/ MINOVA Study)
Clinical Cancer Research, Vol. 30, Núm. 1, pp. 176-186
-
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
Nature Communications, Vol. 15, Núm. 1
-
Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study
Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 732-738
-
Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers
British Journal of Surgery, Vol. 111, Núm. 3
-
Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer
European Journal of Cancer, Vol. 202
-
Current Management and Future Perspectives in Metastatic HER2-Positive Breast Cancer
Seminars in Oncology Nursing, Vol. 40, Núm. 1
-
Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming
Immunological Reviews, Vol. 321, Núm. 1, pp. 143-151
-
Dendritic Cells in Cancer Immunology and Immunotherapy
Cancers, Vol. 16, Núm. 5
-
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266
-
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
Journal of Clinical Oncology, Vol. 42, Núm. 1, pp. 47-58
-
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Gynecologic Oncology, Vol. 187, pp. 128-138
-
Fcγ receptors and immunomodulatory antibodies in cancer
Nature Reviews Cancer, Vol. 24, Núm. 1, pp. 51-71
-
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial
Gynecologic Oncology, Vol. 184, pp. 168-177
-
Impact of a longitudinal course on medical professionalism on the empathy of medical students
Patient Education and Counseling, Vol. 119
-
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study
Gynecologic Oncology, Vol. 186, pp. 182-190
-
Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study
Cancer